Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methods for think-aloud interviews in health-related resource-use research: the PECUNIA RUM instrument.

Expert review of pharmacoeconomics & outcomes researchยท2023
Same author

The Rise of Supportive Oncology: A Revolution in Cancer Care.

Clinical oncology (Royal College of Radiologists (Great Britain))ยท2023
Same author

Proper understanding of recurrent stress urinary incontinence treatment in women (PURSUIT): a randomised controlled trial of endoscopic and surgical treatment.

Trialsยท2022
Same author

COVID-19 confessions: a qualitative exploration of healthcare workers experiences of working with COVID-19.

BMJ openยท2020
Same author

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.

BMC cancerยท2020
Same author

Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale.

Thrombosis researchยท2020

Related Experiment Video

Updated: Jul 10, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Aldesleukin (recombinant interleukin-2).

S Noble1, K L Goa

  • 1Adis International Limited, Auckland, New Zealand.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Aldesleukin (recombinant interleukin-2) shows modest efficacy for metastatic melanoma, with promising response rates in combination therapies but uncertain survival benefits. Further Phase III studies are needed to determine its clinical value against standard chemotherapy.

More Related Videos

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
08:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

Related Experiment Videos

Last Updated: Jul 10, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
08:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

Area of Science:

  • Immunology
  • Medical Oncology

Background:

  • Aldesleukin, a biological response modifier, mimics endogenous interleukin-2 (IL-2) with immunomodulatory properties.
  • While approved for renal cell carcinoma, Aldesleukin is frequently used off-label for metastatic melanoma, with numerous noncomparative trials assessing its efficacy.

Purpose of the Study:

  • To evaluate the efficacy and safety of Aldesleukin in treating metastatic melanoma.
  • To assess the role of Aldesleukin in various immunotherapy and chemoimmunotherapy regimens for melanoma.

Main Methods:

  • Review of noncomparative clinical trials involving Aldesleukin for metastatic melanoma.
  • Analysis of response rates, survival times, and adverse events associated with Aldesleukin treatment.
  • Consideration of different administration routes (continuous intravenous infusion, subcutaneous) and patient selection strategies.

Main Results:

  • Durable complete responses observed in a small subset of patients with good performance status.
  • Median survival times typically around 10-11 months.
  • Combination chemoimmunotherapy with Aldesleukin achieved high response rates (up to 56%), but not consistently linked to improved survival.
  • Improved administration methods and patient selection reduced toxicity.

Conclusions:

  • Aldesleukin demonstrates modest efficacy in metastatic melanoma, with promising response rates in combination therapies.
  • The overall clinical value compared to standard chemotherapy requires determination through randomized Phase III studies.
  • Careful risk-benefit assessment, considering toxicity and quality of life, is crucial for individual patient management.